Loading...
See More

GSK offers rebate if rival drug is better

Dec 24 2010 11:24 Reuters

Related Articles

Pfizer withdraws life-threatening drug

Pfizer axing 800 scientists

Pfizer to be fined $2.3bn

Pfizer agrees to settle case

Pfizer to pay record penalty

 

London - Britain's state-run health service will get a partial rebate from GlaxoSmithKline if the company's new kidney cancer drug Votrient does not match up to a rival medicine in a head-to-head clinical trial.

The unusual deal, the first of its kind, hints at the type of complex arrangements that could become commonplace as Britain moves to a system of value-based drug pricing from the end of 2013.

Draft guidance from cost-effectiveness watchdog the National Institute for Health and Clinical Excellence (NICE) on Friday recommends Votrient for use on the National Health Service (NHS), as long as GSK offers the special price scheme.

The deal provides for a straight 12.5% discount to bring the cost of Votrient to the NHS into line with that of Pfizer's Sutent, and also guarantees a financial rebate if Votrient proves inferior to Sutent in the clinical trial.

The results of the study will not be known until mid-2012.

"If we fail to confirm that they are comparable in efficacy - which we do not expect - then we provide a rebate back to the NHS as a result," GSK's head of British operations, Simon Jose, told Reuters.

"We are moving in the direction where price is driven by value and value is driven by evidence, and therefore we can start to construct different sorts of arrangements where we can balance this off."

The exact scale of the potential rebate has not been disclosed. The monthly cost of Votrient and Sutent - both of which are tablets - is just under £2 000 per patient.

Carole Longson, NICE's health technology evaluation centre director, said the rebate scheme made Votrient a cost-effective proposition. The drug offers patients an additional option and, for some, a more favourable side effect profile, she said.

NICE expects to issue final guidance on Votrient in February 2011.

Modest seller

Votrient, also known by its chemical name pazopanib, is seen as a modest seller for GSK in the next few years, with global sales expected to reach $314m in 2014, according to consensus forecasts from Thomson Reuters Pharma.

Both Votrient and Sutent are so-called protein kinase inhibitors, a relatively new class of targeted cancer treatment. Other new drugs for kidney cancer have been rejected by NICE and GSK has previously failed to persuade NICE to endorse its Tyverb drug for breast cancer.

Jose said it was often difficult to demonstrate the full value of new cancer medicines initially and the idea of linking prices to longer-term scientific evidence could be a model for future negotiations between government and industry.

The British government outlined plans last week for a radical shake-up of medicines policy from the end of 2013, after which it will introduce a system of "value-based" pricing. 

pfizer  |  glaxosmithkline  |  cancer  |  drugs
NEXT ON FIN24X

 
 
 

Read Fin24’s Comments Policy

24.com publishes all comments posted on articles provided that they adhere to our Comments Policy. Should you wish to report a comment for editorial review, please do so by clicking the 'Report Comment' button to the right of each comment.

Comment on this story
0 comments
Add your comment
Comment 0 characters remaining
 

Company Snapshot

We're talking about:

Small Business

Retailers of any shape and size can now unlock the power of mobile transacting.
 
 

3 sports games you have to watch this weekend

Whether it’s date night or a braai with buddies, plan around these three exciting sporting games!

 
 

Men24.com

Everyday struggles of naturally skinny guys
And this year's Miss Bumbum title goes to...
How to maintain your mo, bro
Hottie of the day: Colette

Money Clinic

Money Clinic
Do you have a question about your finances? We'll get an expert opinion.
Click here...
Loading...